Abstract 143P
Background
Oesophageal cancer is the sixth leading cause of cancer-related mortality with more than 90% of oesophageal cancer being squamous cell carcinomas (ESCC) in Asian countries. Prognosis of ESCC remains extremely poor and identification of better prognostic factors is an unmet need.
Methods
We investigated the immune- histochemical expression of Notch1, Notch2, Notch 3, HES-1 (Hairy enhancer of Split -1) (a downstream transcription factor) and p21 among ESCC and non-tumour controls. Non-tumour controls consisted of diagnostic biopsies of GERD patients in which Barrett’s and erosive esophagitis had been ruled out. We also investigated the association of these markers with clinico-pathological features and survival. We included 46 patients of ESCC and 42 controls. IHC markers were performed according to the standard guidelines and analysed with a semi-quantitative H –score (The H score was calculated as: H score= D X I with values ranging from 1-15).
Results
The median age was 60 (37-78 years). M:F ratio was 30: 16. 65.2 % were smokers and 19.6 % were tobacco chewers. 38 cases were locally advanced (Stage III) and 8 were metastatic at baseline. Palliative intent therapy was offered to 24 % and definitive therapy to 76%. An ECOG -PS of 1,2 and 3 was observed in 26, 16 and 4 patients respectively. At a median follow up of 50.67 months, the median overall survival was10.47 mon (range= 8.23-15.1) mon. Using a cut-off score of 7.5 to define positivity, NOTCH 1,2,3 as well as p21 were found to be significantly over-expressed in ESCC as compared to normal controls, while there was no difference in Hes1 expression. Location, grade, baseline metastases, duration of symptoms showed no association with NOTCH 1,2 or 3 positivity. On univariate analysis, male sex, age >60 years, smokers, ECOG-PS>1, Notch 3 H score was found significant. On multivariate analysis, smokers (HR = 3.53, p = 0.013), ECOG-PS>1 (HR = 2.88, p = 0.006) and Notch3 H score (HR = 2.38, p = 0.047) emerged as independent adverse prognostic factors.
Conclusions
NOTCH 1,2 and 3 are highly expressed in ESCC as compared to controls. Notch3 H score is an independent predictor of survival in ESCC and merits evaluation in larger studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Raja Pramanik.
Funding
Intramural Research Fund, Research Section, All India Institute of Medical Sciences, New Delhi.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract